

Amplitude Therapeutics Enters Strategic Collaboration With Lilly

Client News

August 19, 2026

Gunderson Dettmer represented Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, in its strategic research collaboration and licensing agreement with Eli Lilly and Company (“Lilly”).

Amplitude’s taRNA approach is designed to separate the replicase and antigen-encoding RNA components, enabling flexible antigen design, formulation tuning, and dose optimization across vaccine programs. The collaboration will focus on discovering and developing taRNA vaccine candidates for undisclosed infectious disease programs with high unmet need.

“Our ambition at Amplitude is to build a leading in vivo RNA platform by advancing both taRNA and LNP technologies with significant potential to expand what is possible across vaccines and therapeutics,” said Dr. Cory Sago, Chief Executive Officer of Amplitude Therapeutics, [in the announcement of the collaboration](#). “This collaboration gives us the opportunity to translate and validate our taRNA technology across multiple vaccine programs targeting infectious diseases with high unmet need, leveraging Lilly’s global development, manufacturing and commercialization scale.”

The Gunderson deal team was led by Tim Ehrlich, Joel Diamond, and Tim Kulis and included Julie Bateman and Ryan Moser.

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Joel T. Diamond

PARTNER

P +1 617 648 9136

Timothy J. Kulis

PARTNER

P +1 617 648 9236

Julie Bateman

ASSOCIATE

P +1 617 648 9201

Ryan J. Moser

ASSOCIATE

P +1 617 648 9244

Related Services

Life Sciences

Life Sciences Licensing & Strategic Partnering

Private & Public Companies

Featured Insights

CLIENT NEWS

Integrity Growth Partners Leads Prevalent AI's \$22 Million Growth Investment

FIRM NEWS

PitchBook Q2 2026 Global League Tables Reaffirm Gunderson Dettmer as #1 Law Firm for Venture-Backed Deals Across All Financing Stages

PUBLIC VENTURES

SEC Fully Withdraws from Rule 14a-8 Shareholder Proposal No-Action Process

CLIENT NEWS

Genera Announces \$10 Million Financing

CLIENT NEWS

High Definition Vehicle Insurance Acquired by Federated Mutual Insurance Company

CLIENT NEWS

Tarsus Pharmaceuticals Announces Oversubscribed \$125 Million Private Placement Equity Financing

CLIENT NEWS

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals

CLIENT NEWS

Maximum Emerges From Stealth With \$30 Million Seed Financing

FIRM NEWS

India Business Law Journal Recognizes Gunderson Dettmer for Excellence in India-Related Work

FIRM NEWS

Benjamin Teo Recognized in Asian Legal Business Singapore Rising Stars 2026

CLIENT NEWS

Abstract Announces \$25 Million Financing

CLIENT NEWS

Andreessen Horowitz Leads Atoms' Financing